GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Beijing SL Pharmaceutical Co Ltd (SZSE:002038) » Definitions » Intrinsic Value: Projected FCF

Beijing SL Pharmaceutical Co (SZSE:002038) Intrinsic Value: Projected FCF : ¥5.16 (As of Jun. 05, 2025)


View and export this data going back to 2004. Start your Free Trial

What is Beijing SL Pharmaceutical Co Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2025-06-05), Beijing SL Pharmaceutical Co's Intrinsic Value: Projected FCF is ¥5.16. The stock price of Beijing SL Pharmaceutical Co is ¥6.98. Therefore, Beijing SL Pharmaceutical Co's Price-to-Intrinsic-Value-Projected-FCF of today is 1.4.

The historical rank and industry rank for Beijing SL Pharmaceutical Co's Intrinsic Value: Projected FCF or its related term are showing as below:

SZSE:002038' s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 1.04   Med: 1.72   Max: 4.42
Current: 1.35

During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Beijing SL Pharmaceutical Co was 4.42. The lowest was 1.04. And the median was 1.72.

SZSE:002038's Price-to-Projected-FCF is ranked better than
57.84% of 619 companies
in the Drug Manufacturers industry
Industry Median: 1.61 vs SZSE:002038: 1.35

Beijing SL Pharmaceutical Co Intrinsic Value: Projected FCF Historical Data

The historical data trend for Beijing SL Pharmaceutical Co's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beijing SL Pharmaceutical Co Intrinsic Value: Projected FCF Chart

Beijing SL Pharmaceutical Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.77 6.12 6.74 7.12 5.38

Beijing SL Pharmaceutical Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.10 7.10 5.94 5.38 5.16

Competitive Comparison of Beijing SL Pharmaceutical Co's Intrinsic Value: Projected FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Beijing SL Pharmaceutical Co's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beijing SL Pharmaceutical Co's Price-to-Projected-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Beijing SL Pharmaceutical Co's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Beijing SL Pharmaceutical Co's Price-to-Projected-FCF falls into.


;
;

Beijing SL Pharmaceutical Co Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get Beijing SL Pharmaceutical Co's Free Cash Flow(6 year avg) = ¥150.25.

Beijing SL Pharmaceutical Co's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Mar25)*0.8)/Shares Outstanding (Diluted Average)
=(9.5203515959648*150.2544+5618.416*0.8)/1149.210
=5.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Beijing SL Pharmaceutical Co  (SZSE:002038) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Beijing SL Pharmaceutical Co's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=6.98/5.155896239017
=1.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Beijing SL Pharmaceutical Co Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Beijing SL Pharmaceutical Co's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Beijing SL Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
No.69 Fu shi Road, No.1 Building, Bitongyuan, Haidian district, Beijing, CHN, 100049
Beijing SL Pharmaceutical Co Ltd is a Chinese biotechnology-pharmaceutical company. It is principally focused on developing and marketing gene engineering drugs. The product portfolio of the company includes drugs for Oncology, Hepatopathy and Senile disease. Its products include Filgrastim, Asparaginase, Dasartinib, Enoxaparin, Naftopidil, Ademetionine, Lenalidomide, and others.
Executives
Liang Shu Jie Secretary, Director
Xu Ming Bo Directors, executives
Yang Zhong Fan Supervisors
Chen Yu Lin Director
Qi Yan Ming Supervisors
Xi Wen Ying Executives
Wu Yan Zhuo Executives
Wang Wen Xin Director
Li Ya Jun Executives
Zhao Xia Securities Affairs Representative
Zhang Chun Lei Supervisors
Wang Yong Bo Directors, executives
Lu An Jing Supervisors
Wei Su Yan Director

Beijing SL Pharmaceutical Co Headlines

No Headlines